SABS Share Price Performance
US$3.41
0.15 (4.60%)
Price US$3.41
Share Pricen/a
SAB Biotherapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
SABS Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
SAB Biotherapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -3.56
- -26,174.56%
- -32,306.71%
- 0%
About SABS
- Founded
- 2014
- Employees
- 63
- CEO
- WebsiteView website
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
